Works by Zer, Alona

Results: 39
    1

    Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: an open-label, 3-arm, phase II pilot study.

    Published in:
    Neuro-Oncology Advances, 2022, v. 4, n. 1, p. 1, doi. 10.1093/noajnl/vdab188
    By:
    • Peled, Nir;
    • Kian, Waleed;
    • Inbar, Edna;
    • Goldstein, Iris M.;
    • Zemel, Melanie;
    • Rotem, Ofer;
    • Rozenblum, Anna B.;
    • Nechushtan, Hovav;
    • Dudnik, Elizabeth;
    • Levin, Daniel;
    • Zer, Alona;
    • Keren-Rosenberg, Shoshana;
    • Yust-Katz, Shlomit;
    • Fuchs, Vered;
    • Remilah, Areen A.;
    • Shelef, Ilan;
    • Roisman, Laila C.
    Publication type:
    Article
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14

    Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program.

    Published in:
    Therapeutic Advances in Medical Oncology, 2022, p. 1, doi. 10.1177/17588359221103206
    By:
    • Illini, Oliver;
    • Fabikan, Hannah;
    • Swalduz, Aurélie;
    • Vikström, Anders;
    • Krenbek, Dagmar;
    • Schumacher, Michael;
    • Dudnik, Elizabeth;
    • Studnicka, Michael;
    • Öhman, Ronny;
    • Wurm, Robert;
    • Wannesson, Luciano;
    • Peled, Nir;
    • Kian, Waleed;
    • Bar, Jair;
    • Daher, Sameh;
    • Addeo, Alfredo;
    • Rotem, Ofer;
    • Pall, Georg;
    • Zer, Alona;
    • Saad, Akram
    Publication type:
    Article
    15
    16

    Efficacy and Safety of BRAF Inhibitors With or Without MEK Inhibitors in BRAF-Mutant Advanced Non-Small-Cell Lung Cancer: Findings From a Real-Life Cohort.

    Published in:
    2019
    By:
    • Dudnik, Elizabeth;
    • Bar, Jair;
    • Peled, Nir;
    • Bshara, Elias;
    • Kuznetsov, Teodor;
    • Cohen, Aharon Yonathan;
    • Shochat, Tzippy;
    • Nechushtan, Hovav;
    • Onn, Amir;
    • Agbarya, Abed;
    • Moskovitz, Mor;
    • Keren, Shoshana;
    • Popovits-Hadar, Noa;
    • Urban, Damien;
    • Mishaeli, Moshe;
    • Rabinovich, Natalie Maimon;
    • Brenner, Ronen;
    • Zer, Alona;
    • Rotem, Ofer;
    • Roisman, Laila C.
    Publication type:
    journal article
    17
    18
    19
    20
    21
    22
    23

    Primary cardiac sarcomas: A multi‐national retrospective review.

    Published in:
    Cancer Medicine, 2019, v. 8, n. 1, p. 104, doi. 10.1002/cam4.1897
    By:
    • Chen, Tom Wei‐Wu;
    • Loong, Herbert H.;
    • Srikanthan, Amirrtha;
    • Zer, Alona;
    • Barua, Reeta;
    • Butany, Jagdish;
    • Cusimano, Robert J.;
    • Liang, Yun‐Chieh;
    • Chang, Chin‐Hao;
    • Iakobishvili, Zaza;
    • Razak, Albiruni R. Abdul;
    • Lewin, Jeremy
    Publication type:
    Article
    24

    A phase II study of ENMD-2076 in advanced soft tissue sarcoma (STS).

    Published in:
    Scientific Reports, 2019, v. 9, n. 1, p. N.PAG, doi. 10.1038/s41598-019-43222-6
    By:
    • Veitch, Zachary;
    • Zer, Alona;
    • Loong, Herbert;
    • Salah, Samer;
    • Masood, Maryam;
    • Gupta, Abha;
    • Bradbury, Penelope A.;
    • Hogg, David;
    • Wong, Andrew;
    • Kandel, Rita;
    • Charames, George S.;
    • Abdul Razak, Albiruni R.
    Publication type:
    Article
    25
    26
    27
    28
    29
    30
    31
    32
    33
    34
    35
    36
    37
    38

    ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data.

    Published in:
    Oncologist, 2022, v. 27, n. 1, p. e76, doi. 10.1093/oncolo/oyab005
    By:
    • Moskovitz, Mor;
    • Dudnik, Elizabeth;
    • Shamai, Sivan;
    • Rotenberg, Yakir;
    • Popovich-Hadari, Noa;
    • Wollner, Mira;
    • Zer, Alona;
    • Gottfried, Maya;
    • Mishaeli, Moshe;
    • Rosenberg, Shoshana Keren;
    • Onn, Amir;
    • Merimsky, Ofer;
    • Urban, Damien;
    • Peled, Nir;
    • Maimon, Natalie;
    • Bar, Jair
    Publication type:
    Article
    39

    The Impact of Comprehensive Genomic Profiling (CGP) on the Decision-Making Process in the Treatment of ALK-Rearranged Advanced Non-Small Cell Lung Cancer (aNSCLC) After Failure of 2<sup>nd</sup>/3<sup>rd</sup>-Generation ALK Tyrosine Kinase Inhibitors (TKIs)

    Published in:
    Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.874712
    By:
    • Raphael, Ari;
    • Onn, Amir;
    • Holtzman, Liran;
    • Dudnik, Julia;
    • Urban, Damien;
    • Kian, Waleed;
    • Cohen, Aharon Y.;
    • Moskovitz, Mor;
    • Zer, Alona;
    • Bar, Jair;
    • Rabinovich, Natalie Maimon;
    • Grynberg, Shirly;
    • Oedegaard, Cecilie;
    • Agbarya, Abed;
    • Peled, Nir;
    • Shochat, Tzippy;
    • Dudnik, Elizabeth
    Publication type:
    Article